The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants

Jay A. Pandit, Jennifer M. Radin, Danielle Chiang, Emily Spencer, Jeff Pawelek, Mira Diwan, Leila Roumani, Michael Mina
doi: https://doi.org/10.1101/2022.11.14.22282195

Article Information

doi 
https://doi.org/10.1101/2022.11.14.22282195
History 
  • November 15, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Jay A. Pandit1,*,
  2. Jennifer M. Radin1,
  3. Danielle Chiang1,
  4. Emily Spencer1,
  5. Jeff Pawelek1,
  6. Mira Diwan1,
  7. Leila Roumani2 and
  8. Michael Mina2
  1. 1Scripps Research Translational Institute, La Jolla, California
  2. 2eMed, Miami, Florida
  1. ↵*Corresponding author:
    Jay A. Pandit, MD, Scripps Research Translational Institute, 3344 N Torrey Pines Ct. Plaza Level, La Jolla, CA 92037, USA, (858) 784-2028, jpandit{at}scripps.edu
Back to top
Posted November 15, 2022.
Download PDF
Data/Code
Email
The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants
Jay A. Pandit, Jennifer M. Radin, Danielle Chiang, Emily Spencer, Jeff Pawelek, Mira Diwan, Leila Roumani, Michael Mina
medRxiv 2022.11.14.22282195; doi: https://doi.org/10.1101/2022.11.14.22282195
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area